Account
News

Kymriah gets NICE approval for DLBCL

06/02/2019

Author:

Graham Foxon, PhD, MBA
About the Author

Article Tags

NICE Oncology Pricing

Share this article

Related articles

Insider Insights
16.02.2026
TrumpRx: Structural Shift or Symbolic Gesture? 

TrumpRx, the most recent direct-to-consumer platform aimed at cutting drug prices for Amer...

Read more
Articles
28.01.2026
If You’re a Market Access Lead in 2026: How to N...

In 2026, U.S. policy shifts will link domestic US prices to internatio...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch